James Loerop, Chief Business Officer at Aclaris Therapeutics (NASDAQ:ACRS), reported a large insider buy on August 28, according to a new SEC filing.
What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that Loerop purchased 14,705 shares of Aclaris Therapeutics. The total transaction amounted to $99,958.
Aclaris Therapeutics shares are trading up 12.58% at $7.43 at the time of this writing on Tuesday morning.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.